Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Down – Time to Sell?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) shares gapped down before the market opened on Tuesday. The stock had previously closed at $21.79, but opened at $20.37. Chugai Pharmaceutical shares last traded at $21.30, with a volume of 32,124 shares traded.

Analyst Upgrades and Downgrades

CHGCY has been the topic of a number of research reports. Nomura raised Chugai Pharmaceutical to a “hold” rating in a report on Tuesday, September 1st. UBS Group downgraded Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. One investment analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat, Chugai Pharmaceutical currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Trading Up 0.2%

The firm has a 50-day simple moving average of $20.75 and a two-hundred day simple moving average of $24.66. The company has a market capitalization of $71.85 billion, a price-to-earnings ratio of 23.73 and a beta of 0.60.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings data on Tuesday, October 27th. The company reported $0.27 earnings per share (EPS) for the quarter. Chugai Pharmaceutical had a return on equity of 23.76% and a net margin of 35.09%. Equities research analysts anticipate that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 EPS for the current year.

About Chugai Pharmaceutical

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company that develops, manufactures and markets prescription medicines. Its operations focus on addressing unmet medical needs through biotechnology, antibody engineering and other advanced drug-discovery technologies.

The company’s principal therapeutic areas include oncology, hematology, immunology, rheumatology, neuroscience, renal diseases and bone disorders. Its portfolio includes medicines such as Actemra (tocilizumab), used in several inflammatory conditions; Hemlibra (emicizumab), a treatment for hemophilia A; Alecensa (alectinib), an oncology medicine; and Enspryng (satralizumab), used for neuromyelitis optica spectrum disorder.

Founded in Japan in 1925, Chugai is headquartered in Tokyo and primarily serves the Japanese market while also commercializing products internationally through its strategic relationship with Roche.